AnaptysBio (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday, Zacks.com reports.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other brokerages have also weighed in on ANAB. Stifel Nicolaus lowered shares of AnaptysBio from a “buy” rating to a “hold” rating and cut their target price for the company from $124.00 to $74.00 in a research note on Friday, June 21st. Credit Suisse Group lowered shares of AnaptysBio from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $137.00 to $79.00 in a research note on Friday, June 21st. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, SunTrust Banks dropped their price objective on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating on the stock in a research note on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. AnaptysBio presently has an average rating of “Buy” and a consensus target price of $111.25.
Shares of ANAB traded down $1.81 during trading hours on Monday, reaching $50.20. 14,435 shares of the company traded hands, compared to its average volume of 198,746. The firm has a fifty day moving average price of $56.88. The stock has a market cap of $1.41 billion, a P/E ratio of -20.04 and a beta of 1.37. AnaptysBio has a 12 month low of $50.54 and a 12 month high of $110.00.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. As a group, equities analysts expect that AnaptysBio will post -3.76 EPS for the current year.
In other AnaptysBio news, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $73.76, for a total value of $1,654,289.28. Following the completion of the transaction, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the transaction, the insider now directly owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The disclosure for this sale can be found here. Insiders own 14.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System raised its holdings in AnaptysBio by 1.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 10,147 shares of the biotechnology company’s stock worth $741,000 after buying an additional 140 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in AnaptysBio by 6.3% in the second quarter. Janney Montgomery Scott LLC now owns 4,226 shares of the biotechnology company’s stock worth $238,000 after buying an additional 251 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in AnaptysBio by 30.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,298 shares of the biotechnology company’s stock worth $73,000 after buying an additional 306 shares during the last quarter. Aperio Group LLC purchased a new position in AnaptysBio in the second quarter worth about $45,000. Finally, Los Angeles Capital Management & Equity Research Inc. raised its holdings in AnaptysBio by 8.6% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 10,835 shares of the biotechnology company’s stock worth $791,000 after buying an additional 860 shares during the last quarter.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Read More: When can a hold rating present a buying opportunity?
Get a free copy of the Zacks research report on AnaptysBio (ANAB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.